Clinical trials: COPD (Chronic Obstructive Pulmonary Disease)
- Condition COPD (Chronic Obstructive Pulmonary Disease)
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum.
- Trial name
- DACOTA (NCT01285167)
- Testing
- Daxas
- Where
- 605 sites in Germany
- Volunteers
- 3,645 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT05987371
- Testing
- TQC3721 suspension for inhalation, Salbutamol sulfate inhalation aerosol
- Where
- 11 sites in China
- Volunteers
- 75 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00138671
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 88 sites in United States, Brazil and 3 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease (COPD)
A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects
This is a First in Human study to assess the safety and tolerability of AZD7624, following inhaled administration of single ascending doses in healthy male volunteers and female volunteers of non-child bearing potential.
- Trial name
- NCT01754844
- Testing
- AZD7624
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT06527144
- Testing
- 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation
- Where
- 28 sites in China
- Volunteers
- 240 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma, Chronic Obstructive Pulmonary Disease
PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians
The purpose of conducting this study is to obtain PK data of Beclometasone Dipropionate (BDP)/Beclometasone-17-MonoPropionate (B17MP), Formoterol Fumarate (FF) and Glycopyrronium Bromide (GB) after inhalation of CHF 5993 in…
- Trial name
- NCT03859414
- Testing
- Therapeutic Dose 1, Therapeutic Dose 2, Supra-therapeutic Dose
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BRIGHT (NCT01294787)
- Testing
- indacaterol and glycopyrronium bromide (QVA149), tiotropium
- Where
- 13 sites in Germany, Spain
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium…
- Trial name
- NCT05127304
- Testing
- Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol
- Where
- United States
- Volunteers
- 11,316 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population.
- Trial name
- A7881010 (NCT00783406)
- Testing
- PF-00610355
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)
Prospective randomized study with a cross-over design. Mobi™ is a relatively new POC in the market and thus it is valuable to collect data from COPD patients using supplemental oxygen, and their use on Mobi™.
- Trial name
- NCT04107493
- Testing
- Portable Oxygen Cylinder, Mobi
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive…
- Trial name
- NCT02249247
- Testing
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 577 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed.
- Trial name
- NCT00558285
- Testing
- indacaterol/glycopyrrolate, indacaterol, glycopyrrolate
- Where
- 40 sites in Australia, Belgium and 6 more
- Volunteers
- 257 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01682863
- Testing
- QVA149, QAB149
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 614 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Efficacy of NIV Masks in COPD
A randomized controlled pilot study to compare the efficacy and tolerability of a two different NIV masks on carbon dioxide in participants with stable chronic obstructive pulmonary disease (COPD) with chronic type II respiratory…
- Trial name
- NCT04947852
- Testing
- Investigation Mask, Comparator Mask
- Where
- New Zealand
- Volunteers
- 16 people
- Sponsor
- Fisher and Paykel Healthcare
Pulmonary Disease, Chronic Obstructive
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
- Trial name
- NCT02182635
- Testing
- Ba253BINEB
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according…
- Trial name
- NCT01036763
- Where
- 352 sites in Germany
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
The timing of initiating short-term treatment for COPD exacerbations with oral corticosteroids and/or antibiotic therapy has been shown to influence the recovery time of exacerbations with early initiation of exacerbation therapy…
- Trial name
- NCT01431911
- Testing
- Early maintenance treatment, Delayed Maintenance treatment
- Volunteers
- 3,806 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe COPD
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
- Trial name
- INDOS-B (NCT06531798)
- Testing
- Breztri Aerosphere
- Where
- 6 sites in India
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose…
- Trial name
- NCT01854658
- Testing
- GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005)
- Where
- 113 sites in United States
- Volunteers
- 1,615 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.